Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600015 · ClinicalTrials.gov registry record · Phase 2
Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 166
- Enrollment target
NCT00600015 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 166 participants.
The verdict
NCT00600015, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 166 participants
- Enrollment target
Study Summary
This trial will investigate the use of the newer targeted agents erlotinib and sorafenib in patients with stage IIIB or stage IV NSCLC who have received 1-2 prior chemotherapy regimens. Patients will be randomized to receive erlotinib (150 mg/day) and sorafenib (400 mg twice daily), or erlotinib (150 mg/day) and a placebo.
Interventions
- DRUG Erlotinib + Sorafenib
- DRUG Erlotinib + Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00600015
The ClinicalTrials.gov registry entry for NCT00600015 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Erlotinib + Sorafenib is the first listed.
NCT00600015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00600015 about?
NCT00600015 is a clinical study titled "Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)". This trial will investigate the use of the newer targeted agents erlotinib and sorafenib in patients with stage IIIB or stage IV NSCLC who have received 1-2 prior chemotherapy regimens. Patients will be randomized to receive erlotinib (150 mg/day) and sorafenib (400 mg twice daily), or erlotinib (15...
What is the current status of trial NCT00600015?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2008-02. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00600015?
The interventions under investigation include: Erlotinib + Sorafenib (DRUG), Erlotinib + Placebo (DRUG).
Who is sponsoring clinical trial NCT00600015?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.